Travere Therapeutics Scheduled to Report Q3 2026 Earnings
Travere Therapeutics (NASDAQ:TVTX) is set to release its third-quarter 2026 financial results on Monday, November 2nd, following the close of regular trading. The upcoming report will provide critical insight into the company's current growth trajectory and operational efficiency. Market analysts have established a consensus revenue estimate of $195.29 million, representing an 18.4% increase year-over-year. However, earnings per share (EPS) are expected to be $0.42, which marks a projected decline of 28.8% compared to the same period last year.
Tickers: $TVTX
Topics: earnings release EPS estimates revenue estimates
Read the full article at Seeking Alpha
Part of the story Manulife Reports Record Core Earnings and Strong Asian Growth in Q3 2026 (106 articles)